版本:
中国

BRIEF-Pluristem provides shareholder update on corporate, clinical developments

May 22 Pluristem Therapeutics Inc:

* Pluristem provides shareholder update on corporate and clinical developments

* Says study results showed that all three doses of PLX-R18 improved survival rates compared to control group

* Pluristem Therapeutics -as of March 31, 2017, co had $33.1 million in cash, cash equivalents, bank deposits, restricted deposits and marketable securities

* Pluristem Therapeutics Inc - does not expect necessary clarifications regarding agreement with innovative medical to be provided by end of H1/2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐